Leap Therapeutics, Inc. (LPTX)
$
0.37
-0.02 (-5.41%)
Key metrics
Financial statements
Free cash flow per share
-1.4360
Market cap
16.2 Million
Price to sales ratio
0
Debt to equity
0.0074
Current ratio
2.4126
Income quality
0.8568
Average inventory
0
ROE
-1.6215
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Leap Therapeutics, Inc., a biopharmaceutical company focused on acquiring and developing therapies for cancer treatment, presents a compelling picture of its operational performance. The operating income ratio is 0.00 indicating the company's operational profitability margin. In managing its financial commitments, the company incurred an interest expense of $0.00 reflecting its debt servicing obligations. Furthermore, the organization reported selling, general, and administrative expenses of $12,846,000.00 indicating its operational overhead costs. The income before tax ratio stands at 0.00 reflecting the pre-tax margin, while the operating expenses amount to $70,057,000.00 encompassing various operational costs incurred as part of its business activities. These figures illustrate the financial landscape within which Leap Therapeutics operates, as it strives to advance its clinical programs, particularly its lead candidate, DKN-01, aimed at inhibiting Dickkopf-related protein 1 in treating various cancer types. In addition to its robust operational focus, Leap Therapeutics is also characterized by its market positioning and valuation. The stock is affordable at $0.37 suitable for budget-conscious investors seeking exposure to the biotechnology sector. However, the stock has a low average trading volume of 2,164,766.00 indicating lower market activity which might suggest cautious investor interest. With a market capitalization of $15,531,525.00 the company is classified as a small-cap player, which often reflects growth potential and volatility. As a key player in the Biotechnology industry, Leap Therapeutics significantly contributes to the overall market landscape while driving innovation and growth within the competitive Healthcare sector. This strategic positioning allows the company to pursue new therapeutic avenues and solidify its role in advancing cancer treatments, making it a noteworthy entity in the biopharmaceutical field.
Is Leap Therapeutics, Inc. (LPTX) a good investment?
Investing in Leap Therapeutics, Inc. (LPTX) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B, with a Bullish outlook. Always conduct your own research before investing.
What is Leap Therapeutics, Inc. (LPTX)'s stock forecast?
Analysts predict Leap Therapeutics, Inc. stock to fluctuate between $0.22 (low) and $4.79 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Leap Therapeutics, Inc.'s market capitalization?
As of 2025-05-29, Leap Therapeutics, Inc.'s market cap is $15,531,525, based on 41,439,500 outstanding shares.
How does Leap Therapeutics, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Leap Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Leap Therapeutics, Inc. (LPTX) stock?
To buy Leap Therapeutics, Inc. (LPTX) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for LPTX. Place an order (Market, Limit, etc.).
What is the best time to invest in Leap Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Leap Therapeutics, Inc. stock ever split?
Leap Therapeutics, Inc.'s last stock split was 1:10 on 2023-06-21.
How did Leap Therapeutics, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$1.81 | Growth: -54.52%.
Where can I find Leap Therapeutics, Inc.'s investor relations reports?
Visit https://www.leaptx.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Leap Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Leap Therapeutics, Inc. stock?
All-time high: $41.70 (2021-09-30) | All-time low: $0.22 (2025-04-04).
What are the key trends affecting Leap Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
prnewswire.com
17 days ago
CAMBRIDGE, Mass. , May 13, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter of 2025.
prnewswire.com
a month ago
FL-501 fully restored body composition and reversed key indicators of cachexia in preclinical models Findings confirm GDF-15's role in cachexia and support advancing FL-501 into the clinic CAMBRIDGE, Mass. , April 25, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced it will present preclinical data of FL-501 in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting taking place April 25-30 in Chicago, Illinois.
prnewswire.com
2 months ago
Virtual KOL Event on Wednesday, April 23, 2025, at 2:30 p.m. ET CAMBRIDGE, Mass.
seekingalpha.com
2 months ago
Leap Therapeutics (NASDAQ:LPTX ) Conference Call to discuss Updated Data from Part B of the DeFianCe Study March 26, 2025 8:00 AM ET Company Participants Douglas Onsi - President and CEO Cyndi Sirard - Chief Medical Officer Jason Baum - Chief Scientific Officer Conference Call Participants Matthew Pipps - William Blair Swayampakula Ramakanth - H.C. Wainwright Operator Good morning.
benzinga.com
2 months ago
Leap Therapeutics, Inc. LPTX presented updated preliminary data on Wednesday from Part B of the DeFianCe Phase 2 trial of sirexatamab (DKN-01) in combination with bevacizumab and chemotherapy (Experimental Arm) compared to bevacizumab and chemotherapy (Control Arm).
prnewswire.com
2 months ago
Leap to host a conference call to present updated CRC clinical data today, March 26, 2025, at 8:00 a.m. ET CAMBRIDGE, Mass.
prnewswire.com
2 months ago
Updated data confirms statistically significant 32% higher ORR and 3.5 month longer PFS in second-line CRC patients with high DKK1 levels treated with sirexatamab plus bevacizumab and chemotherapy Statistically significant 22% higher ORR and 2.6 month longer PFS in patients who had not had prior anti-VEGF therapy Leap to host a conference call to present clinical data today, March 26, 2025, at 8:00 a.m. ET CAMBRIDGE, Mass.
prnewswire.com
4 months ago
35% objective response rate (ORR) in second-line colorectal cancer (CRC) patients treated with sirexatamab (DKN-01) plus bevacizumab and chemotherapy, compared to 23% ORR in the control arm DKK1 levels highly correlated with clinical activity in CRC population ORR benefit with sirexatamab observed across multiple potential Phase 3 CRC populations Preparations will begin for a registrational Phase 3 study in second-line CRC patients DisTinGuish Part C study in gastric cancer demonstrates activity in biomarker populations, but not the signal necessary to advance into Phase 3 Leap to host a conference call to present clinical data today, January 28, 2025, at 8:00 a.m. ET CAMBRIDGE, Mass.
seekingalpha.com
5 months ago
Leap Therapeutics focuses on developing DKN-01, a promising monoclonal antibody for solid tumors, with encouraging early trial data in GI cancers. LPTX has a short operational runway with less than a year's worth of funds, making future funding a critical concern. Key phase 2 trial readouts for DKN-01 are expected in 2025, which could significantly impact the company's valuation and investment potential.
prnewswire.com
5 months ago
CAMBRIDGE, Mass. , Jan. 6, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E.
See all news
